Table 1.

Characteristics of patients with transient vision loss (TVL) after intravitreal administration of aflibercept, using the established vial system vs. the newer PFS system.

Characteristics of patients with TVL	Vial system	Prefilled syringe
Number of eyes with TVL/total, no. (%)	2 / 842 (0.24%) π	11 / 878 (1.25%) ƒ
Sex
Male, no. (%)	2 (100)	5 (50)
Female, no. (%)	0 (0)	5 (50)
Age mean ± SD, in years	83 ± 1.4	75.6 ± 9.2
Eye
Right, no. (%)	1 (50)	3 (27.3)
Left, no. (%)	1 (50)	8 (72.7)
Prior injections, mean no. ± SD	16.5 ± 15.5	15.1 ± 14.7
Reason for treatment*
Neovascular AMD, no. (%)	2 (100)	6 (54.5)
Diabetic macular edema, no. (%)	0 (0)	2 (18.2)
Central retinal vein occlusion, no. (%)	0 (0)	2 (18.2)
Branch retinal vein occlusion, no. (%)	0 (0)	1 (9.1)
Other, no. (%)	0 (0)	0 (0)
Other ocular comorbidities*
Ocular hypertension, no. (%)	1 (50)	0 (0)
Glaucoma, no. (%)	0 (0)	5 (45.5)
Eyes with TVL prior to observation period, no. (%)*	0 (0)	1 (9.1)°
Surgeons involved in TVL events, no.	2	5^
Need for paracentesis, no. ¥*	0 (0)	8 (72.7) Ω

^1π2 eyes with TVL in 2 patients.

^ƒ 11 eyes with TVL in 10 patients.

^*percentage of the total number of eyes with TVL.

^°one prior TVL event was documented in this case.

^{^}surgeon 1: 4 events; surgeon 2: 3 events; surgeon 3: 2 events; surgeons 4 and 5: 1 event.

^¥the need for paracentesis was assessed individually by the surgeon based on the duration of loss of perception of hand motion, palpation of the globe and the individual spontaneous tendency for resolution including the patient’s subjective course of symptoms within the first 2 min.

^Ωa paracentesis was performed at least once by 5 out of the 6 surgeons (83.3%).